Table 1. Basic features and quality assessments of the included studies.
| Studies | Design | Intervention(I/C) | No. ofPatients | Age (years) | ProstateVolume (cc) | PSA(ng/ml) | Qmax (ml/s) | PVR (ml) | QoL | IPSS | Follow-up(months) | QualityScore |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kim,201411 | CCT | TMLRP/TUPKP | 43/43 | 71.0 ± 7.1/70.5 ± 8.2 | NA/NA | 5.2 ± 4.0/4.6 ± 5.7 | 7.8 ± 4.3/8.4 ± 4.4 | 106.7 ± 114.5/92.4 ± 82.7 | NA/NA | 26.4 ± 5.7/25.0 ± 4.0 | 1 | 5 |
| Yang,201312 | RCT | TMLRP/TUPKP | 79/79 | 62.4 ± 7.2/61.4 ± 6.9 | 72.4 ± 21.2/69.2 ± 23.1 | 2.4 ± 1.2/2.3 ± 1.2 | 8.7 ± 2.8/9.1 ± 3.2 | 79.5 ± 29.3/72.4 ± 28.1 | 3.9 ± 1.2/4.9 ± 1.3 | 22.7 ± 4.3/23.4 ± 3.7 | 1,3,6,12,18 | 3 |
| Wei,201313 | RCT | TMLRP/TUPKP | 45/45 | 69.8 ± 8.1/69.0 ± 7.0 | 112.8 ± 28.3/115.0 ± 39.4 | 6.3 ± 3.9/5.3 ± 4.2 | 8.1 ± 3.2/7.9 ± 2.9 | 90.0 ± 50.4/96.8 ± 42.9 | 4.4 ± 0.8/4.5 ± 0.9 | 21.6 ± 6.7/21.1 ± 7.0 | 1,6,12,18 | 3 |
| Peng,201314 | RCT | TMLRP/TUPKP | 50/50 | 75.3 ± 8.1/74.6 ± 7.9 | 57.8 ± 11.9/58.2 ± 14.7 | 4.2 ± 3.1/3.8 ± 3.3 | 7.9 ± 4.3/8.2 ± 3.9 | 97.1 ± 34.5/88.0 ± 37.6 | 4.6 ± 1.2/4.5 ± 1.3 | 20.3 ± 7.8/19.3 ± 8.2 | 3 | 3 |
| Liu,201115 | CCT | TMLRP/TUPKP | 43/86 | 74.8 ± 7.6/73.2 ± 6.9 | 72.0 ± 18.8/68.0 ± 16.9 | 3.7 ± 1.3/3.4 ± 1.6 | 4.5 ± 1.8/3.6 ± 2.1 | 132.0 ± 42.0/148.0 ± 49.0 | 5.1 ± 0.8/5.8 ± 0.9 | 23.3 ± 4.7/27.2 ± 4.8 | 6 | 5 |
| Wang,200816 | CCT | TMLRP/TURP/TUPKP | 44/42/51 | 71.0(49–86)/71.0(49–86)/71.0(49–86) | NA/NA/NA | NA/NA/NA | 6.5 ± 3.1/6.5 ± 2.8/6.8 ± 2.9 | 145.0 ± 50.4/125.0 ± 35.1/110.2 ± 40.2 | 4.6 ± 1.3/4.9 ± 1.1/4.7 ± 1.1 | 28.3 ± 2.3/27.9 ± 2.5/27.7 ± 2.4 | 3 | 5 |
| Yan,201317 | RCT | TMLRP/TURP | 40/40 | 72.5 ± 7.9/74.5 ± 6.5 | 52.9 ± 12.3/54.3 ± 11.1 | 2.6 ± 2.1/2.8 ± 2.1 | 7.5 ± 2.6/7.8 ± 2.8 | 73.8 ± 35.0/74.9 ± 35.6 | NA/NA | 21.7 ± 4.2/22.6 ± 5.6 | 3 | 3 |
| Cui,201318 | RCT | TMLRP/TURP | 47/49 | 67.8 ± 10.1/70.4 ± 7.0 | 48.0 ± 18.3/54.8 ± 27.4 | 3.4 ± 2.6/3.7 ± 2.7 | 8.6 ± 3.9/8.4 ± 3.4 | 91.9 ± 119.3/59.8 ± 106.4 | 4.4 ± 1.1/4.4 ± 1.0 | 21.1 ± 6.2/20.2 ± 6.7 | 12,24,36,48 | 3 |
| Swiniarski,201219 | RCT | TMLRP/TURP | 54/52 | 68.3 ± 6.8/69.3 ± 7.2 | 62.0 ± 23.7/66.5 ± 22.0 | 3.3 ± 2.0/3.7 ± 2.7 | 7.7 ± 3.5/8.5 ± 3.6 | 166.2 ± 110.5/152.0 ± 112.2 | 4.7 ± 1.0/4.9 ± 1.0 | 20.3 ± 2.5/20.8 ± 6.0 | 1,3 | 3 |
| Shao,201220 | RCT | TMLRP/TURP | 88/80 | 72.3 ± 6.3/71.1 ± 8.1 | 61.3 ± 16.8/59.6 ± 14.2 | NA/NA | 6.5 ± 2.1/6.8 ± 1.8 | 145.4 ± 98.4/137.5 ± 77.1 | 4.6 ± 1.5/1.8 ± 0.9 | 18.4 ± 6.2/19.2 ± 5.7 | 3,6,12 | 4 |
| Fu,201021 | RCT | TMLRP/TURP | 58/42 | 68.2 ± 8.9/65.8 ± 8.4 | 49.8 ± 10.4/48.2 ± 7.6 | 2.2 ± 1.4/2.4 ± 1.5 | 6.5 ± 1.8/7.3 ± 2.4 | 197.4 ± 23.6/186.8 ± 37.2 | 4.8 ± 0.6/4.4 ± 0.7 | 22.6 ± 4.5/21.2 ± 3.7 | 1,3,6,12 | 3 |
| Xia,200822 | RCT | TMLRP/TURP | 52/48 | 68.9 ± 7.7/69.3 ± 7.3 | 59.2 ± 17.7/55.1 ± 16.3 | 2.1 ± 1.1/2.3 ± 1.4 | 8.0 ± 2.8/8.3 ± 3.0 | 93.1 ± 32.1/85.0 ± 36.7 | 4.7 ± 0.9/4.5 ± 1.1 | 21.9 ± 6.7/20.8 ± 5.8 | 1,6,12 | 4 |
| Jia,200923 | CCT | TMLRP/TURP | 30/30 | 74.0 ± 5.5/72.7 ± 7.7 | 58.0 ± 7.5/54.0 ± 6.5 | NA/NA | 8.0 ± 4.0/7.5 ± 3.9 | NA/NA | 4.3 ± 0.8/4.2 ± 0.7 | 19.0 ± 8.3/20.1 ± 7.3 | 1 | 5 |
| Zhuo,200724 | RCT | TMLRP/TURP | 66/58 | 74.3 ± 7.2/73.7 ± 8.0 | 58.4 ± 12.5/56.6±14.1 | 3.2 ± 3.0/3.5 ± 3.4 | 7.8 ± 4.1/8.1 ± 4.4 | 93.1 ± 32.1/85.0 ± 36.7 | 4.5 ± 1.1/4.4 ± 1.3 | 19.1 ± 8.5/18.2 ± 9.2 | 3 | 3 |
RCT = randomized controlled trial; CCT = clinical controlled trial; TMLRP = thulium laser resection of the prostate; TUPKP = transurethral plasmakinetic prostatectomy; TURP = transurethral resection of the prostate; PSA = prostate-specific antigen; I/C = intervention group/control group; Qmax = maximum urinary flow rate; PVR = post-voiding residual urine volume; QoL = quality of life score; IPSS = international Prostate Symptom Score.